Home › Funds › BRAIDWELL LP › MRVI
BRAIDWELL LP position in MRVI
MARAVAI LIFESCIENCES HLDGS I · Health Care
BRAIDWELL LP reported holding 8,702,921 shares of MRVI (MARAVAI LIFESCIENCES HLDGS I) in its Q2 2026 13F filing — a position valued at US$54.3M, representing 2.14% of its reported portfolio and ranking #14 among its reported holdings. BRAIDWELL LP has disclosed MRVI holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BRAIDWELL LP's MRVI position evolved
BRAIDWELL LP first disclosed a stake in MRVI in Q3 2023 at 3,974,857 shares (US$39.7M). The position peaked in Q3 2024 at 8,353,287 shares, worth US$69.4M. Across 12 filings, BRAIDWELL LP increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 8,702,921 shares valued at US$54.3M — a reduction of -1,537,243 shares quarter over quarter.. Notable position changes include a 27% increase in Q4 2023 (shares rose 32% over the following quarter), a 43% increase in Q1 2024 (shares fell 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.97M | $39.75M | New |
| Q4 2023 | 5.04M | $33.02M | Add |
| Q1 2024 | 7.22M | $62.61M | Add |
| Q2 2024 | 9.02M | $64.61M | Add |
| Q3 2024 | 8.35M | $69.42M | Reduce |
| Q4 2024 | 8.35M | $45.53M | Hold |
| Q1 2025 | 8.35M | $18.46M | Hold |
| Q2 2025 | 8.35M | $20.13M | Hold |
| Q3 2025 | 8.35M | $23.97M | Hold |
| Q4 2025 | 8.35M | $27.15M | Hold |
| Q1 2026 | 10.24M | $28.98M | Add |
| Q2 2026 | 8.70M | $54.31M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MRVI and 13F data
MRVI (MARAVAI LIFESCIENCES HLDGS I) is a Health Care company. 35 other funds we track also report a position in MRVI — the largest reported positions include GTCR LLC (US$125.7M), 12 West Capital Management LP (US$44.1M), Ophir Asset Management Pty Ltd (US$30.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MRVI
- GTCR LLC 20.15M sh · $125.74M · Q2 2026
- 12 West Capital Management LP 7.06M sh · $44.06M · Q2 2026
- Ophir Asset Management Pty Ltd 4.83M sh · $30.12M · Q2 2026
- Monaco Asset Management SAM 2.23M sh · $13.92M · Q2 2026
- Philosophy Capital Management LLC 1.90M sh · $11.86M · Q2 2026
- GENERAL AMERICAN INVESTORS CO INC 1.72M sh · $10.71M · Q2 2026
- Tejara Capital Ltd 1.60M sh · $9.95M · Q2 2026
FAQ
How long has BRAIDWELL LP held MRVI?
BRAIDWELL LP has disclosed MRVI holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is BRAIDWELL LP's current position in MRVI?
As of Q2 2026, BRAIDWELL LP holds 8.70M shares of MRVI (MARAVAI LIFESCIENCES HLDGS I), valued at $54.31M, representing 2.14% of its reported portfolio and ranking #14.
Has BRAIDWELL LP been buying or selling MRVI?
In the latest 13F filing (Q2 2026), BRAIDWELL LP reduced its position in MRVI. The position peaked in Q3 2024 at 8.35M shares.
Which other funds hold MRVI?
Other major institutional holders of MRVI include GTCR LLC, 12 West Capital Management LP, Ophir Asset Management Pty Ltd, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.